Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | F10 | P00742 | 8/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.33 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258601 | 0.87 | PTGS1 (0.41) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL14532774 | 0.84 | PTGS1 (0.50) | PTGS1PTGS2SCN9ACCNA2CDK2 | |
| SCHEMBL5371700 | 0.78 | IKBKB (0.35) | PTGS1PTGS2F10CCNA2CDK2 | |
| SCHEMBL5253419 | 0.71 | CCNA2 (0.46) | F10CCNA2CDK2CCNA1 | |
| SCHEMBL14532848 | 0.70 | ALDH1A1 (0.53) | PTGS1PTGS2 | |
| SCHEMBL5255911 | 0.68 | CCNA2 (0.46) | SCN9ACCNA2CDK2CCNA1PIK3CD | |
| SCHEMBL5336498 | 0.67 | IKBKB (0.53) | — | |
| SCHEMBL3858859 | 0.67 | CCNA2 (0.43) | CCNA2CDK2CCNA1PIK3CDPIK3R2 | |
| SCHEMBL6646538 | 0.67 | FLT3 (0.38) | CCNA2CDK2CCNA1 | |
| SCHEMBL8474734 | 0.67 | PTGS2 (0.71) | PTGS1PTGS2CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | claimed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | PTGS1 18/4885PTGS2 22/4885F10 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.